Grifols S.A. (GRFS)
| Bid | 6.05 |
| Market Cap | 5.99B |
| Revenue (ttm) | 7.36B |
| Net Income (ttm) | 191.49M |
| EPS (ttm) | 0.26 |
| PE Ratio (ttm) | 27.13 |
| Forward PE | 6.63 |
| Analyst | n/a |
| Ask | 8.1 |
| Volume | 103,802 |
| Avg. Volume (20D) | 1,111,257 |
| Open | 7.03 |
| Previous Close | 6.95 |
| Day's Range | 6.97 - 7.06 |
| 52-Week Range | 5.79 - 9.96 |
| Beta | 0.92 |
About GRFS
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunogl...
3 weeks ago · businesswire.com
IBL International collaborates with Grifols on advanced biomarker panelsMÄNNEDORF, Switzerland--(BUSINESS WIRE)--IBL International GmbH, a Tecan company, which develops, manufactures and offers specialty diagnostics, today announced a strategic partnership with Grifols, a...
2 months ago · seekingalpha.com
Grifols: Looking At The Longer-Term 2025-2027 Upside After No SaleGrifols remains a strong long-term investment due to its leading position in the plasma industry and improving financial fundamentals, despite short-term volatility and lack of a dividend. The company...
